SNTI
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Senti Biosciences reported positive FDA RMAT meeting outcomes and provided efficacy and durability updates for SENTI-202 in relapsed/refractory AMLMay 14, 2026
- Senti Biosciences completed enrollment in a Phase 1 trial of SENTI-202 for relapsed or refractory acute myeloid leukemiaFeb 11, 2026
- Senti Bio announces updated SENTI-202 Phase 1 data showing deep MRD-negative remissions in relapsed/refractory AMLDec 9, 2025
- Senti Bio receives FDA RMAT designation for SENTI-202 in relapsed/refractory AMLDec 9, 2025
- Senti Bio determines recommended Phase 2 dose in Phase 1 study of SENTI-202 for relapsed/refractory hematologic malignancies including acute myeloid leukemiaAug 5, 2025